India, April 7 -- Amneal Pharmaceuticals, Inc. (AMRX), Monday announced data from a new analysis of the pivotal RISE-PD Phase 3 study, evaluating the efficacy and safety of CREXONT compared with IR CD/LD in the treatment of patients with Parkinson's disease or PD.
The analysis showed that patients on CREXONT experienced statistically significant improvements in sleep quality, which were measured using Parkinson's Disease Sleep Scale-2 or PDSS-2, showing a mean difference of -2.35 (p<0.0001) in total scores.
Additionally, the participants experienced statistically significant improvements across all PDSS-2 subdomains, including reduced disturbed sleep, improved nighttime motor symptoms, and PD symptoms at night.
Moreover, a separate study...